GSK to Acquire 35Pharma for $950M, Bolstering Cardiopulmonary Pipeline with HS235

summarizeSummary

GSK announced the acquisition of 35Pharma Inc. for $950 million, adding HS235, a promising clinical-stage asset for cardiopulmonary diseases, to its pipeline.

check_boxKey Events

• Acquisition of 35Pharma Inc.

  GSK will acquire 100% of 35Pharma Inc., a clinical-stage biopharmaceutical company, for $950 million in cash.

• Pipeline Expansion with HS235

  The acquisition includes HS235, a potentially best-in-class activin signalling inhibitor that has completed Phase I trials and is set to begin studies for pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF).

• Strategic Fit and Market Potential

  HS235 targets a global market for PH therapies forecast to reach $18 billion by 2032 and offers a differentiated profile with reduced bleeding risk and metabolic benefits, bolstering GSK's Respiratory, Immunology and Inflammation portfolio.

auto_awesomeAnalysis

GSK's acquisition of 35Pharma Inc. for $950 million significantly expands its Respiratory, Immunology and Inflammation (RI&I) portfolio. The key asset, HS235, is a clinical-stage activin signalling inhibitor for pulmonary hypertension (PH), a life-shortening disease with a large addressable market. HS235's differentiated profile, including reduced bleeding risk and potential metabolic benefits, positions it as a potentially best-in-class therapy. This strategic move enhances GSK's long-term growth prospects in a high-value therapeutic area.